

# Material Safety Data Sheet Natural Caffeine USP



Health Hazard	2
Fire Hazard	1
Reactivity	0
Personal Protection	(E



NFPA HMIS Personal Protective Equipment

Section 1.0	Product	<b>Identification and</b>	Company	Information
-------------	---------	---------------------------	---------	-------------

occition the Trouber facilities and company information			
Common Name or Trade Name	Natural Caffeine USP 32 (Anhydrous)	Catalog Number(s)	QPP-001- 01/02/03/04/05
Manufacturer	QUSAC PHARMA INC. 645 boul des Erables Valleyfield Quebec J6T 6G3 Canada	CAS#	58-08-2
Common Name	Natural Caffeine	RTECS	EV6475000
Synonyms	1,3,7-trimethylxanthine	TSCA	TSCA 8(b) inventory: Caffeine
IUPAC	1,3,7-trimethypurine-2,6-dione		
Chemical Formula	C8H10N4O2		
Emergency 24hrs	Canutec 613-996-6666		
Information Business hours	QUSAC Pharma Inc. 450-371-2925		

# **Section 2.0 Composition and Information on Ingredients**

Name	CAS#	LD50	% by Weight	
Natural Caffeine	58-08-2	192 mg/Kg	100	

## **Section 3.0 Hazards Identification**

## **Emergency Overview**

WARNING! HARMFUL IS SWALLOWED OR INHALED. CAUSES IRRITATION TO SKIN, EYES AND RESPIRATORY TRACT. POSSIBLE BIRTH DEFECT HAZARD. MAY CASE DEFECTS BASED ON ANIMAL DATA.



Health Hazard	2
Fire Hazard	1
Reactivity	0
Personal Protection	(E



#### **Potential Health Effects**

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada Toll Free : 1-877-463-3223 Tel : (450) 371-2925 Fax : (450) 371-0526

email: info@qusacpharma.com



Inhalation	Inhalation of dust may irritate the mucous membranes and respiratory tract. High concentrations may produce effects paralleling ingestion.	
Ingestion	Toxic. The adult mean lethal dose is approximately 10 g. Large doses may produce palpitation, excitement, insomnia, dizziness, headache and vomiting	
Skin Contact	Causes irritation to skin, Symptoms include redness, itching and pain	
Eye Contact	Causes irritation, redness and pain	
Chronic Exposure	Excessive use of caffeine may lead to digestive disturbances, constipation, palpitations, shortness of breath and depressed mental states. Possible teratogen. May cause congenital malformation in the fetus	
Section 4.0 First Aid	I Measures	
Inhalation	Remove to fresh air, If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention	
Ingestion	Induce vomiting immediately as directed by medical personnel. Never give anything by mouth to an unconscious person. Get medical attention	
Skin Contact	Immediately flush skin with plenty of water for at least 15 minutes. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.	
Eye Contact	Immediately flush eyes with plenty of water for at least 15 minutes, lifting lower and upper eyelids occasionally. Get medical attention immediately	
Section 5.0 Fire Fig	hting Measures	
Fire	As with most organic solids, fire is possible at elevated temperatures or by contact with an ignition source.	
Explosion	Fine dust dispersed in air in sufficient concentrations, an in the presence of an ignition source is a potential dust explosion hazard.	
Fire Extinguishing Media	Water spray, dry chemical, alcohol foam, or carbon dioxide	
Special Information	In the event of a fire, wear full protective clothing and NIOSH-approved self- contained breathing apparatus with full face piece operated in the pressure demand or other positive pressure mode.	

## **Section 6.0 Accidental Release Measures**

Remove all sources of ignition. Ventilate area of spill. Wear appropriate personal protective equipment as specified in Section 8. Clean up spills in a manner that does not disperse dust into the air. Use non-sparking tools and equipment. Reduce airborne dust and prevent scattering by moistening with water. Pick up spill for recovery or disposal.

## Section 7.0 Handling and Storage

Keep in tightly closed container, stored in a cool, dry, ventilated area. Protect against physical damage. Fiber drum containers must be kept dry and away from excessive moisture. Empty containers of this material may be hazardous when empty since they retain product residues (Dust, Solids); observe all warnings and precautions listed for the product.

# **Section 8.0 Exposure Controls/Personal Protection**

Airborne Exposure Limits None established

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada Toll Free : 1-877-463-3223 Tel : (450) 371-2925 Fax : (450) 371-0526

email: info@qusacpharma.com



The most recent ve	ersion of this document is availab			naci products section
Ventilation System	A system of local and/or general exhaust is recommended to keep employee exposures as low as possible. Local exhaust ventilation is generally preferred because it can control the emissions of the contaminant at its source, preventing dispersion of it into the general work area.			
Personal Respirators	NIOSH Approved, for conditions of use where exposure to the dust or mist is apparent, a half-face dust/mist respirator may be worn. For emergencies or instances where the exposure levels are not known, use a full-face positive-pressure, air-supplied respirator.			
Skin Protection	Wear impervious pro coveralls, as appropri			gloves, lab coat, apron or
Eye Protection	Use chemical safety g possible.	goggles an	d/or full face shield whe	re dusting or splashing is
Section 9.0 Physical	and Chemical Pi	ropertie	s	
Appearance	Crystalline powder Taste Bitter. (Slight.)			Bitter. (Slight.)
Molecular Weight	194.2 g/mole	C	Color	White
pH (1% soln/water)	6.9	S	Solubility	1 gm in 46 ml water
Melting Point	237°C to 239°C	В	Boiling Point	178°C (sublimes)
Specific Gravity	1.23	C	)dor	Odorless
Section 10.0 Stability	and Reactivity D	ata		
Stability	The product is stable under normal conditions of use.			
Conditions of Instability	Excess heat			
Hazardous Decomposition	Burning may produce carbon monoxide, carbon dioxide, nitrogen oxides			
Hazardous Polymerization	Will not occur			
Incompatibilities	Incompatible with strong oxidizers, iodine silver salts, tannins, and strong solutions of caustic alkalis			
Section 11.0 Toxicolo	gical Informatio	n		
	Carcinogenic effects: 3 (Not classifiable for human.) by IARC.			
	Mutagenic effects:	Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. May cause damage to the following organs: heart, gastrointestinal tract, central nervous system (CNS).		e damage to the following
Chronic Effects on Humans		May cause cancer (tumorigen) based on animal studies. May cause reproductive and fetal effects. May cause digestive tract disturbances (increased gastric acid, and pepsin secretion and a decrease in lower esophageal sphincter pressure), cardiovascular disturbances. Since it is a CNS stimulant, it may also affect the Central Nervous System (CNS).		

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada Toll Free: 1-877-463-3223
Tel: (450) 371-2925
Fax: (450) 371-0526
email: info@qusacpharma.com

QUSAC Pharma

## Special Remarks on other Toxic Effects on Humans and Acute Potential Health Effects

May cause gastrointestinal (digestive) tract irritation with epigastric pain, abdominal cramps, nausea, vomiting and diarrhea. Affects metabolism and cardiovascular system including increase in metabolism, flushing, palpitations, rapid heart rate, dysrhythmias, ypotension, blood pressure elevation and weight loss, metabolic acidosis. May affect brain and behavior/central nervous system. Symptoms may include nervousness, anxiety, restlessness, insomnia, dizziness, tremor, seizures, convulsions, hallucinations, somnolence, toxic psychosis, tremors, convulsions, ataxia. May also affect blood, respiration (hyperventilation) and urinary system (mild increase in urinary volume and urinary sodium excretion), and may directly produce hypokalemia.

# **Section 12.0 Ecological Information**

Products of Biodegradation	Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation	Products of degradation are less toxic than the product itself.

# **Section 13.0 Disposal Considerations**

Waste must be disposed of in accordance with federal, state and local environmental Control regulations.

## **Section 14.0 Transport Information**

occion 140 transport information		
TDG Act Canada Classification	Class 6.1 Toxic substances	
DOT Classificatio	Class 6.1 Toxic substances	
Identification (Shipping name)	Alkaloid, solid, n.o.s.	
Identification (Technical name)	(caffeine)	
TDG Special Provisions for Transport	Special Provision 16 regarding the use of Technical name and Shipping names.	
TDG and DOT (Pictogram) ADR (Europe) (Pictograms)	6	

## **Section 15.0 Transport Information**

Other Regulations	OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).		
Other Regulations	EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.		
WHMIS (Canada)	Not controlled under WHMIS (Canada). Does not have a WHMIS classification		
DSCL (EEC)	R22- Harmful if swallowed. R40- Possible risks of irreversible effects. R63- Possible risk of harm to the fetus. S2- Keep out of the reach of children.		

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada Toll Free : 1-877-463-3223 Tel : (450) 371-2925 Fax : (450) 371-0526

email: info@qusacpharma.com





Section 16.0 Other Information			
Validated by Q.C.	Dr. Khaled Abou-Zeid	Date	May 25, 2011
Verified by Q.A.	Peter K Booth	Date	May 29, 2011
Date last revision	June 01 2011	Exspires	June 01 2014

All chemicals may pose unknown hazards and should be used with caution. This Material Safety Data Sheet (MSDS) applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomes contaminated, it may pose hazards not mentioned in this MSDS.

It shall be the user's responsibility to develop proper methods of handling and personal protection based on the actual conditions of use. While this MSDS is based on technical data judged to be reliable, QUSAC Pharma Inc. assumes no responsibility for the completeness or accuracy of the information contained herein.

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada

Toll Free: 1-877-463-3223 Tel: (450) 371-2925 Fax: (450) 371-0526

email: in fo@qusacpharma.com

